Θεραπεία Ασυμπτωματικού Μακρού qt Συνδρόμου · 2012-03-29 ·...
TRANSCRIPT
Θεραπεία Ασυμπτωματικού
Μακρού QT Συνδρόμου
Κων/νος Π. Πολυμερόπουλος, FESC, FACC Δρ Ιατρικής ΑΠΘ
Επιμελητής Β`, Α` Καρδιολογική Κλινική Π.Ν.Θ.
«Γ. Παπανικολάου»
3,015 children, < 12 y.
2,772 pts, 10-20 y.
812 pts
2,759 pts
manifest or concealed LQT1 at baseline Sensitivity 90%
Specificity 92%
+ PV 74%
- PV of 97%
Θεραπευτική Προσέγγιση
Θεραπευτική Προσέγγιση
Μexiletine and LQT 3
Schwartz P. Circulation 1995
Mexiletine would shorten the QT interval in the LQT3 patients
in whom an excessive Na+ inward current appears to prolong
repolarization
Shimizu W. Circulation 1997
6 pts
This interpretation has the dramatic support of the percentage of asymptomatic patients who received an ICD based on genotype
“Even in our center (Mayo Clinic), nearly one quarter of the LQT3
patients, compared with only 6% of the LQT1 patients, were
managed with a treatment strategy that included an ICD during this
contemporary time period. However, to date, none of the LQT3
patients have experienced an appropriate ICD therapy (only
inappropriate shocks), suggesting an over-implant rate even for this
particular genotype”
Συμπεράσματα
Eρωτήματα